Lv51
1080 积分 2022-02-16 加入
The next generation of immunotherapy: keeping lung cancer in check
4小时前
已完结
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
10天前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
23天前
已完结
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
23天前
已完结
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
23天前
已完结
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
1个月前
已完结
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
1个月前
已完结
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes
1个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
1个月前
已完结
Eleven clinical trials that will shape medicine in 2025
1个月前
已完结
皖公网安备34019202002308
